- Home
- BCAT vs ATAI Comparison
BCAT vs ATAI Comparison
Compare BCAT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAT
- ATAI
- Stock Information
- Founded
- BCAT 2020
- ATAI 2018
- Country
- BCAT United States
- ATAI Netherlands
- Employees
- BCAT N/A
- ATAI N/A
- Industry
- BCAT Finance/Investors Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- BCAT Finance
- ATAI Health Care
- Exchange
- BCAT Nasdaq
- ATAI Nasdaq
- Market Cap
- BCAT 1.5B
- ATAI 1.6B
- IPO Year
- BCAT N/A
- ATAI 2021
- Fundamental
- Price
- BCAT $14.49
- ATAI $4.34
- Analyst Decision
- BCAT
- ATAI Strong Buy
- Analyst Count
- BCAT 0
- ATAI 5
- Target Price
- BCAT N/A
- ATAI $14.00
- AVG Volume (30 Days)
- BCAT 308.8K
- ATAI 7.6M
- Earning Date
- BCAT 01-01-0001
- ATAI 11-14-2025
- Dividend Yield
- BCAT 9.38%
- ATAI N/A
- EPS Growth
- BCAT N/A
- ATAI N/A
- EPS
- BCAT 1.43
- ATAI N/A
- Revenue
- BCAT N/A
- ATAI $2,309,000.00
- Revenue This Year
- BCAT N/A
- ATAI $736.04
- Revenue Next Year
- BCAT N/A
- ATAI N/A
- P/E Ratio
- BCAT $11.41
- ATAI N/A
- Revenue Growth
- BCAT N/A
- ATAI 510.85
- 52 Week Low
- BCAT $13.67
- ATAI $1.15
- 52 Week High
- BCAT $16.38
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- BCAT 41.06
- ATAI 33.90
- Support Level
- BCAT $14.41
- ATAI $4.14
- Resistance Level
- BCAT $14.70
- ATAI $5.91
- Average True Range (ATR)
- BCAT 0.13
- ATAI 0.38
- MACD
- BCAT 0.00
- ATAI -0.23
- Stochastic Oscillator
- BCAT 29.35
- ATAI 6.82
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.